CU Anschutz Researchers Develop First-in-Class CAR T Therapy Targeting CD64 for AML

CU Anschutz scientists, led by CU Cancer Center member Mathew Angelos, MD, are developing a homegrown CD64-targeted CAR T therapy to treat relapsed or refractory acute myeloid leukemia, with a phase 1 trial set to launch in 2026.